Carotid Intima-media Thickness and Small Dense Low-density Lipoprotein Cholesterol Increase after One Year of Treatment with Direct-acting Antivirals in Patients with Hepatitis C Virus Infection-Reference-Cited by-同舟云学术

Carotid Intima-media Thickness and Small Dense Low-density Lipoprotein Cholesterol Increase after One Year of Treatment with Direct-acting Antivirals in Patients with Hepatitis C Virus Infection

Published:2019-05-01 Issue:9 Volume:58 Page:1209-1215
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Ichikawa Tatsuki¹²³,Miyaaki Hisamitsu⁴,Miuma Satoshi⁴,Motoyoshi Yasuhide¹,Narita Syouhei¹,Toda Satomi²,Takahashi Youichi²,Honda Tetsurou¹,Yajima Hiroyuki¹,Uehara Ryouhei¹,Hino Naoyuki³⁴,Hori Tomoko¹,Hirata Ryousuke¹,Taura Naota⁴,Nakao Kazuhiko⁴

Affiliation:

1. Department of Gastroenterology, Nagasaki Harbor Medical Center, Japan

2. Innovation and Translational Research Center, Nagasaki Harbor Medical Center, Japan

3. Department of Comprehensive Community Care Systems, Graduate School of Biomedical Sciences, Nagasaki University, Japan

4. Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/58/9/58_1514-18/_pdf

Reference30 articles.

1. 1. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59: 2083-2091, 2014.

2. 2. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet. Infect. Dis. 15: 645-653, 2015.

3. 3. Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 21: 762-768, 2014.

4. 4. Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol 67: 1204-1212, 2017.

5. 5. Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology 65: 804-812, 2016.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipid Profile and Cardiovascular Risk Modification after Hepatitis C Virus Eradication;Pathogens;2024-03-25

2. Effects of sustained viral response on lipid in Hepatitis C: a systematic review and meta-analysis;Lipids in Health and Disease;2024-03-09

3. Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic/Cellular Parameters;Viruses;2024-02-27

4. Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities: A systematic review;Liver International;2024-02-22

5. Improvement of carotid atherosclerosis and peripheral artery disease after hepatitis C virus eradication by direct-acting antivirals;Romanian Journal of Morphology and Embryology;2024-01-04